Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Issued
Ratios

ImmunityBio (IBRX) EBIAT (2016 - 2025)

ImmunityBio (IBRX) has disclosed EBIAT for 12 consecutive years, with -$61.9 million as the latest value for Q4 2025.

  • Quarterly EBIAT fell 4.82% to -$61.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$351.4 million through Dec 2025, up 15.02% year-over-year, with the annual reading at -$351.4 million for FY2025, 15.03% up from the prior year.
  • EBIAT for Q4 2025 was -$61.9 million at ImmunityBio, up from -$67.3 million in the prior quarter.
  • The five-year high for EBIAT was -$59.1 million in Q4 2024, with the low at -$233.4 million in Q4 2023.
  • Average EBIAT over 5 years is -$105.7 million, with a median of -$95.2 million recorded in 2022.
  • The sharpest move saw EBIAT plummeted 184.93% in 2021, then skyrocketed 74.68% in 2024.
  • Over 5 years, EBIAT stood at -$91.6 million in 2021, then dropped by 17.5% to -$107.6 million in 2022, then tumbled by 116.98% to -$233.4 million in 2023, then soared by 74.68% to -$59.1 million in 2024, then dropped by 4.82% to -$61.9 million in 2025.
  • According to Business Quant data, EBIAT over the past three periods came in at -$61.9 million, -$67.3 million, and -$92.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.